UPCC 34418: A phase Ib multicenter study to determine the safety and tolerability of tisagenlecleucel in combination with ibrutinib in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma
Enrolling By Invitation
99 years or below
All
Phase
1
10 participants needed
1 Location
Brief description of study
The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Diffuse Large B-cell Lymphoma']
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 831439
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
